Important Safety Information
Milbemax™ for dogs has a satisfactory safety profile when used as per label directions.
Milbemycin oxime has been safety tested in more than 75 different dog breeds, breeding males, pregnant and lactating females, puppies older than 2 weeks and ivermectin-sensitive Collies.
Praziquantel has been safety tested in breeding males, and pregnant and lactating females. Clinical signs of toxicity may be seen at 20-80 times the recommended dose.
If an animal with adult heartworm infection (and therefore circulating microfilariae) is given Milbemax™ Dog, a mild transient shock-like reaction can occur. To avoid this, dogs should be tested for existing heartworm infection before starting treatment.
This formulation is not suitable for use in cats.
Milbemax™ Cat has a satisfactory safety profile when used as per label directions. It has been tested to a minimum interval of one week between doses.
Milbemax™ Cat has not been safety tested in kittens weighing <0.5kg or aged <6 weeks, therefore use in these groups is not recommended.
Milbemax™ Cat can be used in breeding animals, including toms and pregnant or lactating queens. Praziquantel has demonstrated satisfactory safety margins during all reproductive phases.
Cats should be tested for existing heartworm infection before starting treatment. This formulation is not suitable for use in dogs.
Milbemycin oxime and praziquantel are the active ingredients in Milbemax™.
Milbemycin oxime interferes with nerve transmission in invertebrates, which helps protect against heartworm, roundworm, hookworm and whipworm.
Praziquantel causes muscle spasm in tapeworm, which are then attacked by enzymes and disintegrate. It is effective against both flea and hydatid tapeworm.